Amino acid sequence comparisons between the capsid proteins of several human rhinovirus (HRV) serotypes identified residues potentially involved in the discrimination between the major and the minor group receptors. Amino acids conserved within minor group HRVs were substituted in a full-length cDNA clone of HRV2 for those found at equivalent positions in major group HRVs. Transfection of HeLa cells with RNAs transcribed from seven individual mutated cDNAs gave rise to only two viable viruses; growth characteristics and affinity for the minor group receptor of both were unchanged compared to wild-type. Similar mutations in HRV14 were previously shown to alter the affinity for its receptor; the contact sites between the minor group viruses and the respective receptor may therefore be different.
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With one exception, human rhinoviruses (HRVs) utilize one of two receptors to gain entry into the cell; the majority, referred to as the major group, bind to the protein known as ICAM-1 (intercellular adhesion molecule-l; Abraham & Colonno, 1984; Uncapher et al., 1991) whereas the minor group (about 10% of HRVs) use a protein of about 120K with unknown function (Hofer et al., 1992) . Characteristic surface depressions of the capsids of these small icosahedral RNA-containing viruses are thought to be involved in binding to the receptors. These depressions in the viral capsid (referred to as the' canyon') encircling the fivefold axis of symmetry are only about 3 nm wide; this has led to the hypothesis that amino acid residues in this region are inaccessible to immunoglobulins and therefore are not subject to immunological pressure (Rossmann et al., 1985) . The various rhinovirus serotypes belonging to one receptor group could thus conserve structures important for the interaction with their respective receptors whilst permitting serotypic diversity (Rossmann, 1989) . Furthermore, the hypothesis implies that differences in canyon structure between major and minor group rhinoviruses must be responsible for specific recognition of the two different receptors (' receptor discrimination'). In its simplest form, this would involve a set of amino acid residues conserved at certain positions in major group viruses and a second set common only to minor group viruses. Fig. 1 shows part of a sequence comparison designed to locate potential discriminatory sites. Initial searches showed four possible regions in or on the rim of the canyon, conserved in minor group viruses, but not in major group ones. These were basic residues at positions 1081 (HRV2 numbering; see Skern et al., 1985; and 3182, Ile or Leu at position 3229, and the sequence Thr-Glu-Lys (TEK at positions 1222 to 1224). To investigate the role of these residues in receptor binding, mutants of HRV2 were constructed in VP1 at positions 1081 (1081K:E) and at 1222 to 1224 (substitution of TEK by the corresponding sequences derived from HRV14, HRV39 and HRV89); in VP3 the changes 3182R:T and 3229L:T were made. A further mutant (1148P:G) was constructed which is analogous to that of HRV14 (1155P:G) described by Colonno et al. (1988) ; this latter mutation was shown to strongly increase the affinity of HRV14 for its receptor and to reduce concomitantly the viral plaque size. The role of this amino acid residue was therefore also investigated in minor group receptor interactions.
The plasmid pHRV2/1, from which a full-length infectious RNA can be transcribed in vitro, has been described previously (Duechler et al., 1989 into pHR¥2/1. DNA manipulations were performed using established procedures (Maniatis et al., 1982) ; sitedirected mutagenesis was carried out with synthetic oligonucleotides as described by Taylor et at. (1989) or by PCR methodology (Ho et al., 1989; Herlitze & Koenen, 1990) . For the replacement of the TEK sequence at positions 1222 to 1224, two unique restriction sites (XhoI at nucleotide 2962 and MluI at nucleotide 3010) flanking this sequence were created by site-directed mutagenesis without changing the amino acid sequence; oligonucleotide cassettes carrying the replaced TEK sequences were then introduced. All mutagenized fragments were examined by DNA sequencing. RNA was transcribed in vitro and transfected into HeLa cells as described previously (Duechler et al., 1989) .
The transfected HeLa cells were incubated for 3 days at 34 °C, and the virus titre in the supernatant was measured by plaque tests. Transfection with RNAs transcribed from the wild-type pHRV2/1, mutant HRV2ms~,:G and HRV2a,82mT all gave a yield of about 300 p.f.u./ml. No differences in plaque size and morphology between the wild-type and these mutants were observed. In contrast, no viable virus was recovered upon transfection with RNA carrying the single amino acid changes 1081K:E and 3229L:T or the tripeptide sequence derived from HRV14, HRV39 or HRV89 used to replace the TEK sequence at position 1222.
From the two viable mutants, virus stock was obtained from a single plaque, the RNA was isolated and reversetranscribed. The mutagenized regions were amplified by PCR and the presence of the respective mutations was verified by direct DNA sequencing.
Virus was labelled in vivo with [a~S]methionine and purified as described (Neubauer et al., 1987) ; the binding to HeLa cells as a function of the incubation time was then determined for wild-type HRV2, HRV2msp: ~ and HRV2318~g: T. As can be seen in Fig. 2 , no significant difference in binding between wild-type HRV2 and the mutants was apparent. This is in contrast to binding experiments carried out by Colonno et al. (1988) under similar conditions which showed that twice as much of the corresponding HRV14,155p: a mutant was bound than wild-type HRV14.
In order to check the receptor specificity, competition experiments were carried out to assess whether the mutants still bound to the minor group rhinovirus receptor. When increasing amounts of unlabelled HRV were present during the incubation of HeLa cells with pSS]methionine-labelled mutant virus, binding was reduced only by HRV2 whereas the same amount of unlabelled HRV14 had no effect (Fig. 3) . In a further experiment, radioactive virus was prebound to cells at 4 °C in the presence of 0-1% NaN 3. An excess of wildtype HRV2 was then added and the incubation was continued for 60 rain; neither wild-type nor the mutants HRV2msma and HRV231s2~: ~ were eluted from the cells to a significant extent (data not shown). This again is in contrast to the data obtained for HRV141t~sp: ~ which showed that wild-type virus could be released much more easily than the mutant (Colonno et al., 1988) . Thus, the affinity of the HRV2 mutants for the minor group receptor was not changed with respect to wild-type HRV2.
These data clearly indicate that Pro 148 of VP 1 (which is equivalent to Pro155 in HRV14) is not directly involved in the interaction of HRV2 with its receptor. This is in contrast to the data obtained for HRV14 which point to an important function of this residue in the interaction of HRV14 with ICAM-1 (Colonno et binding is given as a percentage of total counts attached to the cells. The binding assays were carried out as described by Colonno et al. (1988) except that cells were used instead of crude cell membrane preparations. HeLa cells (3 × l0 s) from suspension culture (Wisconsin strain, obtained from R. Rueckert) in 2 ml infection medium (Neubauer et al., 1987) Ef.u. Fig. 3 . Competition of unlabelled HRV2 or HRV14 for the binding of viral mutants to HeLa cell membranes. Crude membranes corresponding to about 1 x 107 HeLa cells (Hofer et al., 1992) were incubated with 20000 c.p.m, of 35S-labelled HRV2114sp: ~ or HRV23182R: T in 500 lal infection medium at room temperature for 45 min in the presence of the indicated number of p.f.u, of unlabelled HRV2 (0) or HRV14 (I), respectively. The membranes were pelleted in an Eppendorf centrifuge at 14000 r.p.m, for 10 min and the radioactivity in the pellets and the supernatants was determined by scintillation counting. The percentage of total counts found in the pellets is indicated. , the latter result could be explained as HRV9 also possesses a Lys at the equivalent position. However, whereas basic, hydrophilic and acidic residues are tolerated by major group viruses at the position corresponding to 1081 in HRV2, Glu was not acceptable for HRV2. No conserved oligopeptide sequence corresponding to the TEK element was evident for major group viruses. The reason why the mutations HRV210Sl~:E, HRV23229:L:T and the 'TEK' mutations are not viable is currently not understood; unfortunately, the threedimensional structure of HRV2 has not yet been determined. However, the structure of HRV1A, which is closely related to HRV2 in the amino acid sequence of the capsid proteins, is known (Kim et aI., 1989) . As HRV1A also belongs to the minor receptor group, its structure was used as a model to predict the positions of the individual amino acids in the capsid of HRV2. Based on this, no indication for steric or electrostatic interference of the amino acid side-chains changed in the mutants was found; moreover, all residues are expected to be on the surface and exposed to solvent.
The transfection efficiency of HRV2 RNA is low; transfection with HRV2 RNA gives only 50 plaques/~tg, with either viral or in vitro transcribed RNA. In contrast, 106 plaques/gg HRV14 RNA can be achieved (Duechler et al., 1989; Skern et al., 1991) . Reasons for this difference are not clear. Thus it was not possible to examine in vivo 35S-labelled viral proteins produced in cells transfected with mutant RNAs. Therefore, we attempted to isolate viral particles from the transfected cells by immunoprecipitation and to amplify virusspecific DNA by reverse transcription and PCR technology. However, amplification of virus-specific DNA remaining from the transfection could never be excluded rendering the results inconclusive. At the present time therefore we cannot exclude that the HRV2~0s~K:~, HRV23229j~:~ and 'TEK' mutations are interfering with steps in the viral life cycle other than attachment to the receptor.
The change of Pro1148 to Gly in HRV2 was without any effect on the affinity of the virus for its cell surface receptor. In HRV14, the equivalent change led to a considerably tighter binding to its corresponding receptor; Prol155 forms a shelf near the bottom of the canyon and seems to prevent the receptor from moving deeper into the viral capsid. The increase in binding affinity upon replacement of this Pro by Gly was therefore interpreted as a reduction of steric hindrance (Giranda et al., 1990) . Since no such effect was seen in HRV2, it is likely that the mode of interaction of HRV minor group serotypes with their receptor is different from those of major group viruses.
Although the outline of the canyon in minor and major group HRVs and poliovirus is quite similar, the fine structure differs considerably. As ICAM-1 and the poliovirus receptor both belong to the immunoglobulin superfamily, it was assumed that the minor group receptor would share structural features with this family and that its interactions with the viral capsid would be similar. However, whether the minor group receptor is also related to this group of proteins remains to be determined. For these reasons it is possible that the attachment site of minor group virions differs considerably from the one identified for major group HRVs (Olson et al., 1993) .
